BRUNK GERALD A 4

What Happened
Gerald A. Brunk, a director of enGene Therapeutics, received a grant of 31,000 derivative shares (an option) on June 16, 2026. The award is reported at $0.00 per share (no cash paid at grant) and thus shows a reported transaction value of $0.00. This was a compensation award (not a purchase or sale of shares).

Key Details

• Transaction date: 2026-06-16; filing date: 2026-06-17 (filed next day; within typical Form 4 timing).
• Transaction type/code: A (grant/award). Reported price: $0.00 per share. Reported value: $0.00.
• Shares granted: 31,000 derivative shares (option).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote: The option “vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.”
• No indication of 10b5-1 plan, tax-withholding, or immediate sale in the filing excerpt.

Context
This was an equity compensation award (an option) to a director — common for aligning management and directors with shareholders. Because it’s an award (not a market purchase or sale), it should be interpreted as compensation-related, not a direct bullish or bearish trading signal. The option vests by the earlier of June 9, 2027 or the 2027 annual meeting; there is no indication the shares were exercised or sold at grant.